Ireland funding dispute over Skyclarys drug
Analysis based on 11 articles · First reported Aug 14, 2026 · Last updated Aug 14, 2026
The decision could affect Biogen's revenue prospects for Skyclarys in Republic of Ireland, though the market impact is limited given the small patient population. The political pressure may lead to a reversal or accelerated review, potentially benefiting Biogen and patient access.
The Republic of Ireland — Health Service Executive (HSE) Drugs Group recommended against reimbursing the drug Skyclarys (omaveloxolone) for the treatment of Friedreich's Ataxia, a rare progressive neuromuscular condition affecting about 200 people in Republic of Ireland. The recommendation, based on an assessment by the Ireland — National Centre for Pharmacoeconomics, cited limitations and uncertainties in clinical efficacy data and a price substantially above the level typically considered cost-effective in Republic of Ireland. Republic of Ireland — Sinn Féin leader Mary Lou McDonald wrote to Taoiseach Micheál Martin urging him to intervene to ensure full transparency around the assessment and to expedite the final decision, which is expected later in August. McDonald noted that Skyclarys has been approved in the European Union since February 2024 and is publicly funded in several European countries. She requested an urgent meeting with patients and families and asked that all avenues for access be examined.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard